Effect of Dapagliflozin on Atrial Fibrillation in Diabetic Patients
Official title: Dapagliflozin in Patients With Atrial Fibrillation
Run by University of Oklahoma · NCT05174052 · Data updated 2026-11-12
This study is testing if the diabetes medication Dapagliflozin can help reduce the heart rhythm problems caused by atrial fibrillation in people with diabetes.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Enrollment | 28 (estimated) |
| Sponsor | University of Oklahoma Academic / other |
| Locations | 1 site (Oklahoma City, Oklahoma) |
| Status | Recruiting |
| Started | June 1, 2022 |
| Main results expected | April 2027 |
| Study ends | December 2027 |
| Registry record updated | April 1, 2026 |
| Trial ID | NCT05174052 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are individuals diagnosed with diabetes mellitus and paroxysmal atrial fibrillation.
✕Probably not a fit
Patients with type 1 diabetes, severe renal impairment, or those currently taking anti-arrhythmic drugs may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the impact of Dapagliflozin on the burden of atrial fibrillation (AF) in patients with diabetes mellitus (DM). Participants diagnosed with paroxysmal AF and DM will be randomized to receive either Dapagliflozin or a placebo. The primary outcome will be measured through continuous heart rhythm monitoring over a two-week period, along with assessments of quality of life and echocardiographic indices. The goal is to explore the therapeutic potential of SGLT2 inhibitors in reducing AF burden and improving patient outcomes.
Why it matters
Potential benefit: If successful, this study could provide a new treatment option for patients with diabetes and atrial fibrillation, potentially reducing AF burden and improving quality of life.
How similar studies have gone: While SGLT2 inhibitors have shown cardiovascular benefits in other studies, this specific approach to atrial fibrillation is novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosed with DM * Paroxysmal AF Exclusion Criteria: * Type 1 DM, * Symptoms of hypotension or systolic blood pressure \<90mmHg, * Severe renal impairment with eGFR\<30mL/minute/1.73m2, * History of lower limb amputation, * Hypersensitivity to Dapagliflozin, * Currently taking any SGLT2i, * Pregnancy, * Currently taking anti-arrhythmic drugs * Undergoing catheter ablation will be excluded
Where it's running
-
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States Recruiting
Study contacts
- Principal investigator: Zain Ul Abideen Asad, MD — University of Oklahoma
- Study coordinator: Aurora Vera
- Email: Aurora-Vera@ouhsc.edu
- Phone: 405-271-8001
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Home-based cardiovascular health screening for people turning 50, 55, 60, 65, 70 or 75 in Uppsala
This trial tests whether giving people a home blood pressure monitor, a dried blood spot kit, and a questionnaire can find more cardiovascular risk factors than usual care.
-
Research on health inequality and genetic disparity in cardiovascular diseases
This study is trying to understand how health differences and genetics affect heart diseases in people from various ethnic backgrounds in the UK to help improve treatments for everyone.
-
AI-based tools to help diagnose, treat and predict stroke outcomes across multiple hospitals
This study tests AI-powered tools on real-world stroke patients to see if they can improve pre-hospital triage, diagnosis, and outcome prediction while data stay securely within each hospital.
-
Preventing lower limb artery disease in adults with diabetes using a risk-prediction model and HAPA-based nursing
A risk-prediction model is tested in adults with type 2 diabetes to see if a nursing plan based on the HAPA model can reduce peripheral artery disease in the legs.
-
Left-atrial Fibrosis in Persistent Atrial Fibrillation and Its Comorbidities
This study tests how comorbid conditions like sleep apnea and primary aldosteronism relate to left-atrial fibrosis and AF recurrence in patients undergoing ablation.
-
Dual Energy ablation with SmartTouch SF catheter in persistent atrial fibrillation
This study tests a pulsed field and radiofrequency ablation system to treat persistent atrial fibrillation in adults who have not responded well to prior medications.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.